Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE

Who May Qualify: - Patients with a diagnosis of non-ST-segment elevation myocardial infarction - A finalized coronary PCI - Male or non-fertile female subjects ≥18 years. (Females without childbearing potential, postmenopausal women and women with a history of hysterectomy or other medical conditions that preclude pregnancy) - Written willing to sign a consent form - A CCTA can be scheduled within 7 days after PCI Who Should NOT Join This Trial: - Has received influenza vaccination within 6 months - Other vaccination planned within 8 weeks (including covid-19 booster doses) - Severe allergy to eggs or previous allergic reaction to influenza vaccine - Cardiac surgery or staged PCI planned within 8 weeks - Coronary stent involving the proximal RCA - Suspicion of febrile illness or acute, ongoing infection - Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol - Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response - Inability to provide willing to sign a consent form - Previous randomization in the ELIMINATE trial - Any non-cardiovascular condition, e.g. malignancy, with a life expectancy of less than 1 year based on the investigator´s clinical judgement. - Contraindication to coronary CT angiography (e.g., inability to lie flat, contraindication to glyceryl trinitrate, previous contrast allergy or contrast-induced nephropathy, severe renal impairment \[eGFR \<30 mL/min/1.73 m2\]) - Atrial fibrillation - Uncontrolled chronic inflammatory disease - Unable to comply with protocol requirements Always talk to your doctor about whether this trial is right for you.